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Abstract:	   	  
We	  report	  the	  case	  of	  an	  86-­‐year-­‐old	  man	  with	  a	  past	  history	  of	  coronary	  disease	  admitted	  to	  our	  
internal	  medicine	  department	  for	  severe	  asthenia	  and	  weakness	  due	  to	  rhabdomyolysis.	  Three	  days	  
earlier,	   he	   had	   been	   discharged	   from	   a	   gastroenterology	   unit	   with	   a	   diagnosis	   of	   amoxicillin–
clavulanate-­‐induced	   acute	   cholestatic	   hepatitis.	   A	   review	   of	   his	   drugs	   revealed	   that	   he	   had	   taken	  
atorvastatin	  10	  mg	  daily	   in	  the	  previous	  six	  years,	  without	  clinical	  or	   laboratory	  signs	  of	  myopathy.	  
Atorvastatin	   was	   therefore	   stopped,	   with	   gradual	   improvement	   of	   the	   rhabdomyolysis.	   All	  
concomitant	  drug	  therapy	  needs	  to	  be	  reassessed	  in	  elderly	  patients,	  especially	  when	  they	  become	  
acutely	  ill.	  
	  






Statin	   myopathy	   is	   a	   common	   concern	   for	   clinicians	   managing	   patients	   with	   dyslipidaemia.	  
Well-­‐known	   risk	   factors	   for	   statin	   toxicity	   include	   advanced	   age,	   female	   gender,	   hypothyroidism,	  
diabetes,	   excessive	   alcohol	   consumption,	   concomitant	   use	   of	   drugs	   that	   increase	   statin	   blood	  
concentration,	   a	   history	   of	  muscle	   complaints	   or	   elevated	   creatine	   kinase	   and	   history	   of	   renal	   or	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dysfunction	  occurs	  de	  novo	   in	  patients	  until	   then	  tolerant	  to	  statins,	  as	  exemplified	  by	  the	  present	  
case	  report.	  
	  
Case	  description	   	  
An	   86-­‐year-­‐old	  man	  with	   a	   past	   history	   of	   coronary	   disease	   (coronary	   artery	   bypass	   grafting	   and	  
percutaneous	  transluminal	  coronary	  angioplasty,	  6	  and	  4	  years	  earlier,	  respectively)	  was	  admitted	  to	  
our	   internal	  medicine	  department	   for	   severe	  asthenia	  and	  weakness	   following	  a	   lipothymic	  event.	  
Three	   days	   earlier,	   he	   had	   been	   discharged	   from	   a	   gastroenterology	   unit	   with	   a	   diagnosis	   of	  
amoxicillin–clavulanate-­‐induced	  acute	  cholestatic	  hepatitis.	  He	  had	  been	  able	  to	  ride	  his	  bicycle	  until	  
the	  day	  before	  his	  first	  hospitalization,	  but	  now	  he	  had	  become	  unable	  to	  get	  up	  and	  walk	  without	  
help.	  At	  physical	  examination,	  he	  appeared	  an	  acutely	  ill	  elderly	  man,	  with	  jaundice,	  severe	  muscle	  
weakness	  and	  brown	  urine.	  Routine	  laboratory	  tests	  showed	  that	  –	  in	  comparison	  to	  those	  obtained	  
at	  discharge	  –	  cholestasis	  indexes	  had	  improved,	  but	  cytonecrosis	  indexes	  and	  kidney	  function	  tests	  
had	  deteriorated,	  with	  clear	  evidence	  of	  rhabdomyolysis	  (Table	  1).	   	  
	  
	   First	  hospital	  stay	   	   Readmission	  
	   Day	  1	   Day	  4	  
(discharge)	  






	   1.44	   	   2.09	   1.45	   2.19	   3.02	   1.72	   1.59	  
Bilirubin	  
















Direct	   14.3	   	   	   10.8	   6.40	   	   	   	   2.7	  
AST	  (U/l)	   229	   236	   	   564	   1,093	   	   	   227	   95	  
ALT	  (U/	  l)	   154	   138	   	   188	   338	   	   	   244	   119	  
GGT	  (U/	  l)	   375	   336	   	   376	   279	   	   	   342	   442	  
ALP	  (U/	  l)	   3,486	   	   	   3,209	   2,320	   	   	   	   1307	  
CPK	  (U/	  l)	   	   	   	   16,839	   28,949	   21,669	   15,754	   1,167	   323	  
Myoglobin	  
(U/	  l)	  
	   	   	   >10,000	   >10,000	   >10,000	   >10,000	   731	   405	  
AST,	   aspartate	   aminotransferase;	   ALT,	   alanine	   aminotransferase;	   GGT,	   gamma-­‐glutamyl	   transpeptidase;	   ALP,	  
alkaline	  phosphatase;	  CPK,	  creatine	  phosphokinase	  
Table	  1:	  Laboratory	  tests	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hyperkinetic	   states,	   alcoholism,	   electrolyte	   abnormalities	   or	   hypothyroidism.	   He	   had	   been	  
prescribed	   amoxicillin–clavulanate	   (1	   g	   twice	   daily	   for	   7	   days)	   by	   his	   general	   practitioner	   for	  
lymphoedema,	  although	  two	  months	  earlier	  he	  had	  had	  malaise,	  not	  better	  specified,	  after	  having	  
received	  the	  same	  drug	  for	  bronchitis.	  A	  review	  of	  his	  drug	  therapy	  revealed	  that	  he	  had	  consumed	  
atorvastatin	   10	   mg	   daily	   in	   the	   previous	   six	   years,	   without	   any	   clinical	   or	   laboratory	   signs	   of	  
myopathy.	   Atorvastatin	   was	   therefore	   promptly	   stopped,	   with	   gradual	   improvement	   first	   of	  
laboratory	  indexes	  and	  later	  of	  clinical	  conditions.	  After	  a	  hospital	  stay	  of	  approximately	  3	  weeks,	  he	  




Statins	  are	  remarkably	  safe	  and	  effective	  in	  preventing	  cardiovascular	  complications	  and	  death	  and	  
have	  become	  the	  most	  prescribed	  class	  of	  drugs	  worldwide.	  Clinical	  trials	  suggest	  that	  muscle	  injury	  
is	  uncommon	  with	  statin	  therapy	  alone,	  with	  estimated	  frequencies	  of	  2–11%	  for	  myalgias,	  0.5%	  for	  
myositis	  and	  <0.1%	  for	  rhabdomyolysis.	  However,	  clinical	  trials,	  based	  on	  patients	  selected	  for	  being	  
at	   low	   risk	   for	   drug-­‐related	   complications,	   may	   underestimate	   the	   true	   prevalence	   of	   statin	  
myopathy	   in	  clinical	  practice2.	  Moreover,	  the	  onset	  of	  muscle	  symptoms	  is	  usually	  within	  weeks	  to	  
months	  after	   the	   initiation	  of	   statin	   therapy,	  but	  may	  occur	  any	   time	  during	   treatment3.	  Clinicians	  
should	  pay	  particular	  attention	  to	  patients’	  vulnerability	  to	  acute	  or	  chronic	  renal	  failure,	  obstructive	  
liver	   disease	   and	   when	   statins	   extensively	   metabolized	   by	   cytochrome	   P-­‐450	   3A4	   (lovastatin,	  
simvastatin,	  atorvastatin)	  are	  administered	  together	  with	  drugs	  that	  interfere	  with	  CYP3A44.	  
Amoxicillin–clavulanate	  liver	  injury	  tends	  to	  occur	  more	  often	  in	  elderly	  male	  patients	  and	  is	  almost	  
always	   associated	   with	   comorbidities	   and/or	   polytherapy	   concomitant	   medications	   with	   known	  
potential	  for	  hepatic	  adverse	  effects5.	   	  
In	  this	  case,	  it	  was	  certainly	  predictable,	  because	  drug	  therapy	  needs	  to	  be	  frequently	  and	  carefully	  
reassessed	  in	  elderly	  patients,	  especially	  when	  they	  become	  acutely	  ill.	  
In	   turn,	   if	   statin	   treatment	   is	   not	   interrupted	   despite	   the	   presence	   of	   acute	   severe	   cholestasis,	  
rhabdomyolysis	  is	  not	  unexpected.	   	  
In	   our	   opinion,	   the	   two	   factors	   that	   led	   to	   this	   potentially	   very	   risky	   situation	   were	   (a)	   the	   false	  
confidence	  created	  by	  this	  gentleman	  tolerating	  atorvastatin	  well	  over	  the	  years	  and	  (b)	  the	  lack	  of	  
attention	  paid	  by	  subspecialists	  to	  the	  complexities	  of	  drug	  therapy	  in	  elderly	  patients	  who	  present	  
with	  multiple	  conditions.	   	  
The	   use	   of	   statins	   in	   the	   very	   elderly	   is	   still	   a	  matter	   of	   debate.	   The	   Heart	   Protection	   Study,	   the	  
PROSPER	   study	   and	   the	   SAGE	   study	   illustrate	   the	   benefit	   of	   statin	   treatment	   on	   coronary	   or	  
surrogate	   end	   points	   in	   higher-­‐risk	   elderly	   patients,	   although	   the	   data	   are	   still	   somewhat	  
controversial,	   particularly	   for	   individuals	   >80	   years	   of	   age.	   Very	   elderly	   people	   are	   likely	   to	   suffer	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circumstances,	  prescribing	  a	   statin	   should	  not	  be	  a	  high	  priority,	  particularly	  when	   treatment	  with	  
multiple	  drugs	  is	  ongoing	  or	  when	  adherence	  is	  an	  issue.	  
In	   conclusion,	   this	   case	  warns	  us	   that	  physicians	   should	  be	  able	   to	  update	   their	  practice	  based	  on	  
experience	  and	   learning	  and	  never	  underestimate	   the	  effect	  of	   intercurrent	  events	   (new	  diseases,	  




• The	  risk	  of	  statin	  myopathy	  needs	  to	  be	  kept	  in	  mind	  during	  the	  course	  of	  new	  diseases	  or	  
following	   the	   administration	   of	   new	   drugs,	   even	   when	   patients	   have	   tolerated	   long-­‐term	  
statins.	  
• In	   such	   circumstances,	   prescribing	   a	   statin	   should	   not	   be	   a	   top	   priority,	   particularly	  when	  
treatment	  with	  multiple	  drugs	  is	  ongoing	  or	  when	  adherence	  is	  an	  issue.	  
• Drug	  therapy	  needs	  to	  be	  frequently	  and	  carefully	  reassessed	  in	  elderly	  patients,	  especially	  
when	  they	  become	  acutely	  ill.	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